Apogee Therapeutics Inc logo

Apogee Therapeutics Inc

APGE
Healthcare|Biotechnology|USA
$133.65
+0.08 (+0.06%)
Tangible Book
$16.77

Clinical Trials (8)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT06395948
A Study Evaluating APG777 in Atopic Dermatitis
Atopic Dermatitis
P2
Active470RCT, Double-blindAPG777, Placebo
NCT07003425
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Atopic Dermatitis
P2
Recruiting350Double-blindAPG777, APG777, APG777
NCT07027527
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
P1
Active86RCT, Open-labelAPG777, APG990, Dupilumab
NCT06920901
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
Asthma
P1
Active31RCT, Double-blindAPG777, Placebo
NCT02757326
ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma
Multiple Myeloma
P1P2
Terminated13Open-labelOpaganib
NCT02939807
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
Carcinoma, Hepatocellular
P2
Withdrawn—Open-labelABC294640
NCT02229981
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
Diffuse Large B Cell Lymphoma, Kaposi Sarcoma
P1P2
Withdrawn—Open-labelABC294640
NCT01488513
ABC294640 in Treating Patients With Advanced Solid Tumors
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
P1
Completed22Open-labelsphingosine kinase-2 inhibitor ABC294640